Impact of highly active antiretroviral therapy on hepatitis C virus protease quasispecies diversity in HIV co-infected patients

Mark A. Winters, Aarthi Chary, Robert Eison, David Asmuth, Mark Holodniy

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Many hepatitis C virus (HCV)-infected patients are also infected with HIV, and undergo antiretroviral (ARV) treatment for their human immunodeficiency virus (HIV) infection. Due to changes in HIV burden and immunologic status, HIV ARV treatment may have indirect effects on the HCV population, which could impact the effectiveness of subsequent HCV protease inhibitor (PI) treatment. The genetic variability of the protease-encoding HCV NS3 gene was evaluated in 10 co-infected patients initiating ARVs (both before and after ARV initiation), and compared to the genetic variability in 10 patients on stable ARV therapy. After RT-PCR of plasma-derived HCV RNA, a mean of 20 clones per patient time-point were sequenced and analyzed for changes in the HCV quasispecies population. No significant differences in sequence diversity or complexity at the nucleic acid or amino acid levels were seen at baseline between groups or between the two time points in either group. HCV protease diversity in the pre- and post-ARV treatment samples was not significantly different than samples from patients on stable ARV therapy. There was no significant development of amino acid substitutions known to confer HCV PI resistance in either group. Initiation of ARV for HIV infection does not significantly alter the genetic diversity or complexity of the HCV NS3 gene or result in increased number of HCV PI-associated amino acid changes. These results suggest ARV treatment for HIV would not affect the efficacy of HCV PI treatment.

Original languageEnglish (US)
Pages (from-to)791-798
Number of pages8
JournalJournal of Medical Virology
Volume82
Issue number5
DOIs
StatePublished - May 2010

Fingerprint

Highly Active Antiretroviral Therapy
Hepacivirus
Peptide Hydrolases
HIV
Protease Inhibitors
Virus Diseases
Therapeutics
Amino Acids
Amino Acid Substitution
Nucleic Acids
Population
Genes
Clone Cells
RNA
Polymerase Chain Reaction

Keywords

  • Antiviral agents
  • Genetic variation
  • Hepatitis C virus
  • HIV
  • Serine endopeptidases

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Impact of highly active antiretroviral therapy on hepatitis C virus protease quasispecies diversity in HIV co-infected patients. / Winters, Mark A.; Chary, Aarthi; Eison, Robert; Asmuth, David; Holodniy, Mark.

In: Journal of Medical Virology, Vol. 82, No. 5, 05.2010, p. 791-798.

Research output: Contribution to journalArticle

@article{345d51d773524542acea62b3134a8ee4,
title = "Impact of highly active antiretroviral therapy on hepatitis C virus protease quasispecies diversity in HIV co-infected patients",
abstract = "Many hepatitis C virus (HCV)-infected patients are also infected with HIV, and undergo antiretroviral (ARV) treatment for their human immunodeficiency virus (HIV) infection. Due to changes in HIV burden and immunologic status, HIV ARV treatment may have indirect effects on the HCV population, which could impact the effectiveness of subsequent HCV protease inhibitor (PI) treatment. The genetic variability of the protease-encoding HCV NS3 gene was evaluated in 10 co-infected patients initiating ARVs (both before and after ARV initiation), and compared to the genetic variability in 10 patients on stable ARV therapy. After RT-PCR of plasma-derived HCV RNA, a mean of 20 clones per patient time-point were sequenced and analyzed for changes in the HCV quasispecies population. No significant differences in sequence diversity or complexity at the nucleic acid or amino acid levels were seen at baseline between groups or between the two time points in either group. HCV protease diversity in the pre- and post-ARV treatment samples was not significantly different than samples from patients on stable ARV therapy. There was no significant development of amino acid substitutions known to confer HCV PI resistance in either group. Initiation of ARV for HIV infection does not significantly alter the genetic diversity or complexity of the HCV NS3 gene or result in increased number of HCV PI-associated amino acid changes. These results suggest ARV treatment for HIV would not affect the efficacy of HCV PI treatment.",
keywords = "Antiviral agents, Genetic variation, Hepatitis C virus, HIV, Serine endopeptidases",
author = "Winters, {Mark A.} and Aarthi Chary and Robert Eison and David Asmuth and Mark Holodniy",
year = "2010",
month = "5",
doi = "10.1002/jmv.21679",
language = "English (US)",
volume = "82",
pages = "791--798",
journal = "Journal of Medical Virology",
issn = "0146-6615",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Impact of highly active antiretroviral therapy on hepatitis C virus protease quasispecies diversity in HIV co-infected patients

AU - Winters, Mark A.

AU - Chary, Aarthi

AU - Eison, Robert

AU - Asmuth, David

AU - Holodniy, Mark

PY - 2010/5

Y1 - 2010/5

N2 - Many hepatitis C virus (HCV)-infected patients are also infected with HIV, and undergo antiretroviral (ARV) treatment for their human immunodeficiency virus (HIV) infection. Due to changes in HIV burden and immunologic status, HIV ARV treatment may have indirect effects on the HCV population, which could impact the effectiveness of subsequent HCV protease inhibitor (PI) treatment. The genetic variability of the protease-encoding HCV NS3 gene was evaluated in 10 co-infected patients initiating ARVs (both before and after ARV initiation), and compared to the genetic variability in 10 patients on stable ARV therapy. After RT-PCR of plasma-derived HCV RNA, a mean of 20 clones per patient time-point were sequenced and analyzed for changes in the HCV quasispecies population. No significant differences in sequence diversity or complexity at the nucleic acid or amino acid levels were seen at baseline between groups or between the two time points in either group. HCV protease diversity in the pre- and post-ARV treatment samples was not significantly different than samples from patients on stable ARV therapy. There was no significant development of amino acid substitutions known to confer HCV PI resistance in either group. Initiation of ARV for HIV infection does not significantly alter the genetic diversity or complexity of the HCV NS3 gene or result in increased number of HCV PI-associated amino acid changes. These results suggest ARV treatment for HIV would not affect the efficacy of HCV PI treatment.

AB - Many hepatitis C virus (HCV)-infected patients are also infected with HIV, and undergo antiretroviral (ARV) treatment for their human immunodeficiency virus (HIV) infection. Due to changes in HIV burden and immunologic status, HIV ARV treatment may have indirect effects on the HCV population, which could impact the effectiveness of subsequent HCV protease inhibitor (PI) treatment. The genetic variability of the protease-encoding HCV NS3 gene was evaluated in 10 co-infected patients initiating ARVs (both before and after ARV initiation), and compared to the genetic variability in 10 patients on stable ARV therapy. After RT-PCR of plasma-derived HCV RNA, a mean of 20 clones per patient time-point were sequenced and analyzed for changes in the HCV quasispecies population. No significant differences in sequence diversity or complexity at the nucleic acid or amino acid levels were seen at baseline between groups or between the two time points in either group. HCV protease diversity in the pre- and post-ARV treatment samples was not significantly different than samples from patients on stable ARV therapy. There was no significant development of amino acid substitutions known to confer HCV PI resistance in either group. Initiation of ARV for HIV infection does not significantly alter the genetic diversity or complexity of the HCV NS3 gene or result in increased number of HCV PI-associated amino acid changes. These results suggest ARV treatment for HIV would not affect the efficacy of HCV PI treatment.

KW - Antiviral agents

KW - Genetic variation

KW - Hepatitis C virus

KW - HIV

KW - Serine endopeptidases

UR - http://www.scopus.com/inward/record.url?scp=77950972192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950972192&partnerID=8YFLogxK

U2 - 10.1002/jmv.21679

DO - 10.1002/jmv.21679

M3 - Article

C2 - 20336744

AN - SCOPUS:77950972192

VL - 82

SP - 791

EP - 798

JO - Journal of Medical Virology

JF - Journal of Medical Virology

SN - 0146-6615

IS - 5

ER -